4.5 Review

The immune response and antibacterial therapy

期刊

MEDICAL MICROBIOLOGY AND IMMUNOLOGY
卷 204, 期 2, 页码 151-159

出版社

SPRINGER
DOI: 10.1007/s00430-014-0355-0

关键词

Antibiotics; Immune response; Bacteria; Host; Infection; Treatment

向作者/读者索取更多资源

The host's immune defence mechanisms are indispensable factors in surviving bacterial infections. However, in many circumstances, the immune system alone is inadequate. Since the 1940s, the use of antibacterial therapy has saved millions of lives, improving the span and quality of life of individuals. Unfortunately, we are now facing an era where antibacterial agents are threatened by resistance. In addition to targeting bacteria, some antibacterial agents affect various aspects of the immune response to infection. Since many antibacterial drugs are failing in efficacy due to resistance, it has been strongly suggested that any synergy between these drugs and the immune response be exploited in the treatment of bacterial infections. This review explores the influence of antibacterial therapy on the immune response and new approaches that could exploit this interaction for the treatment of bacterial infections.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biology

Time dependent asymptotic analysis of the gene regulatory network of the AcrAB-TolC efflux pump system in gram-negative bacteria

George H. Youlden, Vito Ricci, Xuan Wang-Kan, Laura J. V. Piddock, Sara Jabbari, John R. King

Summary: Efflux pumps are mechanisms of resistance in bacteria that can expel antibiotics to confer resistance. Overexpression of efflux pumps can lead to multi-drug resistance. By studying the gene regulation network associated with efflux, a mathematical model is presented and analyzed using time-dependent asymptotic analysis.

JOURNAL OF MATHEMATICAL BIOLOGY (2021)

Article Microbiology

Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance

Christopher A. Darlow, Fernando Docobo-Perez, Nicola Farrington, Adam Johnson, Laura McEntee, Jennifer Unsworth, Ana Jimenez-Valverde, Silke Gastine, Ruwanthi Kolamunnage-Dona, Renata M. A. de Costa, Sally Ellis, Francois Franceschi, Joseph F. Standing, Mike Sharland, Michael Neely, Laura Piddock, Shampa Das, William Hope

Summary: Antimicrobial resistance in neonatal sepsis is a global issue, with high mortality rates in low- and middle-income countries. A combination therapy of fosfomycin and amikacin shows enhanced bactericidal activity and synergy against resistant strains. Monte Carlo simulations support the efficacy of this combination regimen for the treatment of neonatal sepsis.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Article Infectious Diseases

Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations

Elena Carrara, Alessia Savoldi, Laura J. Piddock, Francois Franceschi, Sally Ellis, Mike Sharland, Adrian John Brink, Patrick N. A. Harris, Gabriel Levy-Hara, Anusha Rohit, Constantinos Tsioutis, Hiba Zayyad, Christian Giske, Margherita Chiamenti, Damiano Bragantini, Elda Righi, Anna Gorska, Evelina Tacconelli

Summary: The optimal treatment for carbapenem-resistant Gram-negative bacteria infections varies globally, with dual combination therapy being the preferred treatment scheme. However, there is disagreement among clinicians regarding the definition of 'combination therapy.'

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Review Infectious Diseases

Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli

Luigia Scudeller, Elda Righi, Margherita Chiamenti, Damiano Bragantini, Giulia Menchinelli, Paolo Cattaneo, Christian G. Giske, Thomas Lodise, Maurizio Sanguinetti, Laura J. Piddock, Francois Franceschi, Sally Ellis, Elena Carrara, Alessia Savoldi, Evelina Tacconelli

Summary: The efficacy of combination therapy for carbapenem-resistant Gram-negative bacilli (CR-GNB) infections remains controversial. In vitro studies suggest that combinations of polymyxins and carbapenems show high or moderate synergism against CR-GNB. Well-designed in vitro studies are crucial for guiding the selection of combination therapies in clinical trials and improving the armamentarium against carbapenem-resistant bacteria.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Article Immunology

A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance AMR Solution

Laura J. Piddock, Jean-Pierre Paccaud, Seamus O'Brien, Michelle Childs, Rohit Malpani, Manica Balasegaram

Summary: Antibiotics are crucial for modern medicine, but commercial developers do not see sufficient profitability to address public need. Nonprofit research and development organizations have the potential to collaborate and provide new antibiotics.

CLINICAL INFECTIOUS DISEASES (2022)

Editorial Material Infectious Diseases

BSAC Vanguard Report Series: The future of drug development

Laura J. Piddock

Summary: The discovery of antibiotics revolutionized medicine, but now antimicrobial resistance is becoming a greater problem than the development of new antimicrobials. New political and economic models are needed to address this escalating crisis. This article examines the challenges and proposes strategies to overcome them.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Infectious Diseases

Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants

Maria Laura Ciusa, Robert L. Marshall, Vito Ricci, Jack W. Stone, Laura J. Piddock

Summary: The study found that inhibiting the AcrB efflux pump in Escherichia coli did not significantly increase the expression of other efflux pump genes, indicating that there is no compensatory mechanism to overcome efflux inhibition.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Infectious Diseases

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance

Christopher A. Darlow, Nicola Farrington, Adam Johnson, Laura McEntee, Jennifer Unsworth, Ana Jimenez-Valverde, Ruwanthi Kolamunnage-Dona, Renata M. A. Da Costa, Sally Ellis, Francois Franceschi, Mike Sharland, Michael Neely, Laura J. Piddock, Shampa Das, William Hope

Summary: This study assessed the efficacy of flomoxef and fosfomycin as a potential alternative treatment for neonatal sepsis in low- and middle-income countries. The combination therapy showed synergy in terms of bacterial killing and prevention of fosfomycin resistance. The findings suggest that flomoxef/fosfomycin could be an effective regimen for neonatal sepsis in settings with antimicrobial resistance.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Editorial Material Public, Environmental & Occupational Health

Governing Global Antimicrobial Resistance: 6 Key Lessons From the Paris Climate Agreement

Isaac Weldon, Susan Rogers Van Katwyk, Gian Luca Burci, Thana C. de Campos, Mark Eccleston-Turner, Helen R. Fryer, Alberto Giubilini, Thomas Hale, Mark Harrison, Stephanie Johnson, Claas Kirchhelle, Kelley Lee, Kathleen Liddell, Marc Mendelson, Gorik Ooms, James Orbinski, Laura Iv Piddock, John-Arne Rottingen, Julian Savulescu, Andrew C. Singer, A. M. Viens, Clare Wenham, Mary E. Wiktorowicz, Shehla Zaidi, Steven J. Hoffman

AMERICAN JOURNAL OF PUBLIC HEALTH (2022)

Article Infectious Diseases

EnvR is a potent repressor of acrAB transcription in Salmonella

Jessica M. A. Blair, Pauline Siasat, Helen E. McNeil, Abigail Colclough, Vito Ricci, Amelia J. Lawler, Hind Abdalaal, Michelle M. C. Buckner, Alison Baylay, Stephen J. Busby, Laura J. Piddock

Summary: In this study, it was found that EnvR is a potent repressor of acrAB transcription in Salmonella, and can override binding by RamA, thus preventing multidrug resistance to clinically useful drugs. Finding novel tools to increase EnvR expression may form the basis of a new way to prevent or treat multidrug-resistant infections.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings

Christopher A. Darlow, Laura McEntee, Adam Johnson, Nicola Farrington, Jennifer Unsworth, Ana Jimenez-Valverde, Bhavana Jagota, Ruwanthi Kolamunnage-Dona, Renata M. A. Da Costa, Sally Ellis, Francois Franceschi, Mike Sharland, Michael Neely, Laura Piddock, Shampa Das, William Hope

Summary: The combination of flomoxef and amikacin shows synergistic effects in bacterial killing and prevention of amikacin resistance. It effectively kills a majority of Enterobacterales isolates with a range of flomoxef/amikacin MICs, making it a potentially clinically effective regimen for the empirical treatment of neonatal sepsis in LMIC settings. Further assessment in a clinical trial is recommended.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Editorial Material Infectious Diseases

An interview with Laura Piddock- by Felicity Poole, commissioning editor

Laura Piddock

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2023)

Article Microbiology

Mapping direct and indirect MarA/SoxS/Rob/RamA regulons in Salmonella Typhimurium reveals repression of csgD and biofilm formation

Alistair D. Middlemiss, James R. J. Haycocks, Anne M. Stringer, Laura J. V. Piddock, Joseph T. Wade, David C. Grainger

Summary: The transcription factors MarA, SoxS, Rob and RamA control overlapping stress responses in enteric bacteria and their constitutive expression is linked to antibiotic resistance. The study mapped the binding sites of these factors across the Salmonella Typhimurium genome and identified changes in transcription start sites. This information helps disentangle direct and indirect gene regulation effects and deduce promoter architecture within the regulon. The control of csgD, which is involved in biofilm formation, is particularly sensitive to SoxS repression in Salmonella Typhimurium unlike in Escherichia coli where MarA indirectly regulates csgD expression.

MICROBIOLOGY (2023)

Article Infectious Diseases

Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance

Alasdair P. Macgowan, M. L. G. Attwood, Alan R. Noel, R. Barber, Zachary Aron, Timothy J. Opperman, Elizabeth Grimsey, Jack Stone, Vito Ricci, L. J. Piddock

Summary: This study investigated the pharmacodynamic characteristics of efflux pump inhibitors (EPIs) in Escherichia coli through in vitro experiments and gene sequencing. The results showed that the AUC of chlorpromazine and PA beta N was most closely related to the reduction in bacterial load, while the T > threshold of MBX-4191 was the driver for bacterial load reduction. No changes in population profiles were observed with the combination of ciprofloxacin + EPIs, but mutations were detected in gyrA, gyrB, and marR.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Review Biotechnology & Applied Microbiology

Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections

Ursula Theuretzbacher, Benjamin Blasco, Maelle Duffey, Laura J. V. Piddock

Summary: Advances in genomics, systems biology, protein structure determination, and artificial intelligence provide new opportunities for target-based antibacterial drug discovery. Multiple criteria, including target essentiality, conservation, homology with human genes, and drug-like binding potential, need to be considered in selecting a suitable target. Subcellular location and the risk of drug resistance also play important roles in the process. This review highlights promising targets and inhibitors for Gram-negative bacteria and lessons learned from past drug discovery programs.

NATURE REVIEWS DRUG DISCOVERY (2023)

暂无数据